Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEZS NASDAQ:HILS NYSE:NNVC NASDAQ:NTEC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEZSAeterna Zentaris$3.60+2.2%$3.66$3.96▼$12.00$10.26M1.557,305 shs1,332 shsHILSHillstream BioPharma$1.23-2.1%$1.54$0.19▼$2.65$4.06M3.081.39 million shs6,256 shsNNVCNanoViricides$1.58$1.51$0.94▼$2.34$25.39M0.96248,685 shs61,387 shsNTECIntec Pharma$13.52$8.80▼$36.88$8.65M0.83543,436 shs988,300 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEZSAeterna Zentaris+2.25%-5.89%-1.51%+1.27%-33.43%HILSHillstream BioPharma-2.06%-0.48%-26.99%-18.28%-53.96%NNVCNanoViricides0.00%0.00%+12.06%+19.70%-19.39%NTECIntec Pharma0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEZSAeterna ZentarisN/AN/AN/AN/AN/AN/AN/AN/AHILSHillstream BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ANNVCNanoViricides0.2967 of 5 stars0.05.00.00.00.60.00.0NTECIntec PharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEZSAeterna Zentaris 0.00N/AN/AN/AHILSHillstream BioPharma 0.00N/AN/AN/ANNVCNanoViricides 0.00N/AN/AN/ANTECIntec Pharma 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEZSAeterna Zentaris$2.37M2.72N/AN/A$14.99 per share0.24HILSHillstream BioPharmaN/AN/AN/AN/A$0.48 per shareN/ANNVCNanoViricidesN/AN/AN/AN/A$0.66 per shareN/ANTECIntec PharmaN/AN/AN/AN/A$16.18 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEZSAeterna Zentaris-$16.55M-$14.86N/A∞N/A-760.32%-83.45%-45.76%8/11/2025 (Estimated)HILSHillstream BioPharma-$8.47M-$0.72N/AN/AN/AN/A-188.44%-149.61%N/ANNVCNanoViricides-$8.29M-$0.70N/A∞N/AN/A-87.90%-78.69%N/ANTECIntec Pharma-$14.13M-$16.32N/AN/AN/AN/A-96.37%-68.87%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEZSAeterna ZentarisN/AN/AN/AN/AN/AHILSHillstream BioPharmaN/AN/AN/AN/AN/ANNVCNanoViricidesN/AN/AN/AN/AN/ANTECIntec PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEZSAeterna ZentarisN/A5.945.93HILSHillstream BioPharmaN/A3.013.01NNVCNanoViricidesN/A3.442.47NTECIntec PharmaN/A2.342.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEZSAeterna Zentaris0.73%HILSHillstream BioPharma13.36%NNVCNanoViricides10.30%NTECIntec Pharma22.37%Insider OwnershipCompanyInsider OwnershipAEZSAeterna Zentaris0.10%HILSHillstream BioPharma30.24%NNVCNanoViricides4.60%NTECIntec Pharma3.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEZSAeterna Zentaris201.79 million1.79 millionNo DataHILSHillstream BioPharma117.60 million12.28 millionNot OptionableNNVCNanoViricides2016.07 million14.92 millionOptionableNTECIntec Pharma40898,000N/AOptionableNTEC, NNVC, HILS, and AEZS HeadlinesRecent News About These CompaniesINDP stock touches 52-week low at $0.78 amid market challengesFebruary 12, 2025 | msn.comIndaptus Therapeutics reports Q3 EPS (32c) vs. (47c) last yearNovember 13, 2024 | markets.businessinsider.comFinTechOn 2024: FinTech Associations from 14 Asian Economies Sign MOU to Enhance Collaborations in Anti-FraudNovember 5, 2024 | finance.yahoo.comX4 Pharmaceuticals, Inc. (XFOR)September 21, 2024 | finance.yahoo.comIntec Pharma shares dive after Parkinson's trial failureSeptember 9, 2024 | pharmaphorum.comPINDP Indaptus Therapeutics, Inc.August 23, 2024 | seekingalpha.comQ1 Results, Aug. 14: Ola Electric, Glenmark, HAL To Declare Earnings TodayAugust 14, 2024 | ndtvprofit.comNBuy Rating Affirmed for Indaptus Therapeutics Amid Positive Decoy20 Clinical DevelopmentsAugust 13, 2024 | markets.businessinsider.comMorepen Laboratories Ltd Company SummaryJuly 22, 2024 | indiainfoline.comIWill Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs InMay 14, 2024 | msn.comMinebea Intec Opens Technical CenterMay 10, 2024 | powderbulksolids.comPBuy Rating Affirmed for Indaptus Therapeutics Amid Promising Decoy20 Clinical AdvancementsMay 10, 2024 | markets.businessinsider.comRheinmetall’s MS Motorservice Implements State-of-the-Art High-Bay Storage System in NeuenstadtApril 17, 2024 | news.europawire.euNBuy Rating Affirmed for Indaptus Therapeutics Amid Positive Clinical and Financial OutlookMarch 15, 2024 | markets.businessinsider.comBuy Rating Affirmed on Indaptus Therapeutics as Decoy20 Advances in Phase 1 with Promising DevelopmentsMarch 6, 2024 | markets.businessinsider.comStocks to Watch Today: RVNL,Glenmark Pharma, PB Fintech,Sula Vineyards and moreFebruary 18, 2024 | msn.comChhattisgarh education minister calls for expansion of central schools in the stateFebruary 2, 2024 | msn.comThe 2024 Chicago Titan 100: Here's who made the listNovember 12, 2023 | dailyherald.comDH.C. Wainwright Sticks to Its Buy Rating for Indaptus Therapeutics (INDP)August 15, 2023 | markets.businessinsider.comNGENF - NervGen Pharma Corp.June 15, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNTEC, NNVC, HILS, and AEZS Company DescriptionsAeterna Zentaris NASDAQ:AEZS$3.60 +0.08 (+2.25%) As of 08/8/2025Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Hillstream BioPharma NASDAQ:HILS$1.23 -0.03 (-2.06%) As of 08/8/2025Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.NanoViricides NYSE:NNVC$1.58 0.00 (0.00%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.55 -0.03 (-1.90%) As of 08/8/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.Intec Pharma NASDAQ:NTECIntec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
